» Articles » PMID: 34012606

The Epidemiology and Biology of Pulmonary Metastases

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2021 May 20
PMID 34012606
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Our goal in this chapter is to explore the complex processes of metastasis and why there is a predisposition for this to occur in the lung. In addition, we aim to describe the incidence of pulmonary metastases in various contexts and based on the origin of the primary tumor. There are unique characteristics of the pulmonary system that make metastases more likely to occur in the lung than anywhere else in the body. Some of these characteristics include receiving the entire cardiac output every minute, having the densest capillary bed in the body, and being the first reservoir of most lymphatic drainage entering the venous system. There are multiple postulated routes of metastasis to the pulmonary system including hematogenous and lymphatic routes with early or late dissemination. The vascularization of pulmonary metastases is variable and complex, often recruiting supply from bronchial and pulmonary origin. There are also many biochemical factors in the tumor microenvironment that play a key role in the development of lung metastases including vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), very late antigen 4 (VLA-4) and intercellular adhesion molecule 1 (ICAM-1). Studies vary widely in reported rates of pulmonary metastases due to differences in clinical study design, however, it is commonly accepted that up to half of autopsies performed on patients who died of malignancy have pulmonary metastases. In a surgical series describing the incidence of primary cancer types with resected pulmonary metastases the most common sites were thyroid, colon, breast, genitourinary tract, skin, liver, breast, and adrenal glands.

Citing Articles

Low-Burden Oligometastatic Disease of the Lung Treated with Robotic Stereotactic Ablative Radiotherapy: A Retrospective Study.

Zygogianni A, Koukourakis I, Liakouli Z, Desse D, Georgakopoulos I, Armpilia C Biomedicines. 2025; 13(2).

PMID: 40002930 PMC: 11853336. DOI: 10.3390/biomedicines13020517.


Low Rates of Intrapulmonary Local Recurrence After Laser Metastasectomy: A Single-Center Retrospective Cohort Study of Colorectal Cancer Metastases.

Shalabi A, Shalabi S, Graeter T, Welter S, Ehab A, Kuon J Cancers (Basel). 2025; 17(4).

PMID: 40002277 PMC: 11852527. DOI: 10.3390/cancers17040683.


Retrospective Analysis Comparing Lung-RADS v2022 and British Thoracic Society Guidelines for Differentiating Lung Metastases from Primary Lung Cancer.

Stana L, Mederle A, Avram C, Bratosin F, Barata P Biomedicines. 2025; 13(1.

PMID: 39857714 PMC: 11762811. DOI: 10.3390/biomedicines13010130.


Aspartate signalling drives lung metastasis via alternative translation.

Doglioni G, Fernandez-Garcia J, Igelmann S, Altea-Manzano P, Blomme A, La Rovere R Nature. 2025; 638(8049):244-250.

PMID: 39743589 DOI: 10.1038/s41586-024-08335-7.


Non-invasive surrogate markers of pulmonary hypertension are associated with poor survival in patients with cancer.

Cekay M, Arndt P, Franken J, Wilhelm J, Pullamsetti S, Roller F BMJ Open Respir Res. 2024; 11(1).

PMID: 39179271 PMC: 11344493. DOI: 10.1136/bmjresp-2023-001916.


References
1.
Snyder B, Pugatch R . Imaging characteristics of metastatic disease to the chest. Chest Surg Clin N Am. 1998; 8(1):29-48. View

2.
Ito H, Nakayama H . [Surgical management of pulmonary metastases]. Gan To Kagaku Ryoho. 2010; 37(2):200-3. View

3.
Yoneda K, Louie S, Shelton D . Approach to pulmonary metastases. Curr Opin Pulm Med. 2000; 6(4):356-63. DOI: 10.1097/00063198-200007000-00018. View

4.
Newton T, Preger L . SELECTIVE BRONCHIAL ARTERIOGRAPHY. Radiology. 1965; 84:1043-51. DOI: 10.1148/84.6.1043. View

5.
Filderman A, Coppage L, Shaw C, Matthay R . Pulmonary and pleural manifestations of extrathoracic malignancies. Clin Chest Med. 1989; 10(4):747-807. View